{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:12:01Z","timestamp":1792066321056,"version":"4.4.0"},"reference-count":63,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Frances and Augustus Newman Foundation"},{"name":"Guy\u2019s Cancer Charity"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The addition of platinum chemotherapy to primary radiotherapy (chemoradiation) improves survival outcomes for patients with head and neck squamous cell carcinoma (HNSCC), but it carries a high incidence of acute and long-term treatment-related complications, resulting in a poor quality of life. In addition, patients with significant co-morbidities, or older patients, cannot tolerate or do not benefit from concurrent chemoradiation. These patients are often treated with radiotherapy alone resulting in poor locoregional control and worse survival outcomes. Thus, there is an urgent need to assess other less toxic treatment modalities, which could become an alternative to chemoradiation in HNSCC. Currently, there are several promising anti-cancer drugs available, but there has been very limited success so far in replacing concurrent chemoradiation due to their low efficacy or increased toxicities. However, there is new hope that a treatment strategy that incorporates agents that act as radiosensitisers to improve the efficacy of conventional radiotherapy could be an alternative to more toxic chemotherapeutic agents. Recently, imidazole-based or quinone-based anti-malarial compounds have drawn considerable attention as potential radiosensitisers in several cancers. Here, we will discuss the possibility of using these compounds as radiosensitisers, which could be assessed as safe and effective alternatives to chemotherapy, particularly for patients with HNSCC that are not suitable for concurrent chemotherapy due to their age or co-morbidities or in metastatic settings. In addition, these agents could also be tested to assess their efficacy in combination with immunotherapy in recurrent and metastatic settings or in combination with radiotherapy and immunotherapy in curative settings.<\/jats:p>","DOI":"10.3390\/cancers14194694","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T21:23:27Z","timestamp":1664313807000},"page":"4694","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Abul","family":"Azad","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Campus, New Hunt House, London SE1 1UL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-3948","authenticated-orcid":false,"given":"Anthony","family":"Kong","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Campus, New Hunt House, London SE1 1UL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMra0707975","article-title":"Recent Advances in Head and Neck Cancer","volume":"359","author":"Haddad","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.2015.60.7804","article-title":"Human Papillomavirus-Negative Pharyngeal Cancer","volume":"33","author":"Dillon","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1200\/JCO.2015.61.2358","article-title":"Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials","volume":"33","author":"Bhatia","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Burtness, B., and Golemis, E.A. (2014). EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer. Molecular Determinants of Head and Neck Cancer, Springer.","DOI":"10.1007\/978-1-4614-8815-6"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1002\/cncr.23442","article-title":"Overview of the efficacy of cetuximab in recurrent and\/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies","volume":"112","author":"Vermorken","year":"2008","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1517\/14728214.2015.1031653","article-title":"Emerging drugs for head and neck cancer","volume":"20","author":"Wen","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"viii729","DOI":"10.1093\/annonc\/mdy424.045","article-title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"29","author":"Burtness","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMc076359","article-title":"More on Severe Cutaneous Reaction with Radiotherapy and Cetuximab","volume":"357","author":"Bonner","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1021\/jm061081y","article-title":"Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): Aquation, redox properties, protein binding, and antiproliferative activity","volume":"50","author":"Groessl","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1081\/SL-120016277","article-title":"A spectroscopic study on the DNA binding behavior of the anticancer drug dacarbazine","volume":"35","author":"Wang","year":"2002","journal-title":"Spectrosc. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1039\/C7MD00067G","article-title":"Imidazoles as potential anticancer agents","volume":"8","author":"Ali","year":"2017","journal-title":"Medchemcomm"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20170915","DOI":"10.1259\/bjr.20170915","article-title":"Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: Misonidazole, myths and mistakes","volume":"92","author":"Wardman","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/bjc.1981.65","article-title":"In vitro metabolism of misonidazole","volume":"43","author":"Josephy","year":"1981","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3797\/scipharm.0907-14","article-title":"Synthetic Nitroimidazoles: Biological Activities and Mutagenicity Relationships","volume":"77","author":"Mital","year":"2009","journal-title":"Sci. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1259\/0007-1285-47-560-474","article-title":"Metronidazole (\u201cFlagyl\u201d). A radiosensitizer of hypoxic cells","volume":"47","author":"Asquith","year":"1974","journal-title":"Br. J. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.1982.300","article-title":"A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo","volume":"46","author":"Overgaard","year":"1982","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/31.1.9","article-title":"Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action","volume":"31","author":"Edwards","year":"1993","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/1097-0142(19810701)48:1<43::AID-CNCR2820480111>3.0.CO;2-H","article-title":"Metronidazole and interstitial implantation in the treatment of extensive recurrent head and neck cancers","volume":"48","author":"Orr","year":"1981","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0360-3016(97)00327-1","article-title":"Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas","volume":"39","author":"Chassagne","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0360-3016(95)00150-W","article-title":"Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas","volume":"32","author":"Lee","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0167-8140(95)01538-R","article-title":"The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: Long-term results and side effects prognostic factors","volume":"35","author":"Horiot","year":"1995","journal-title":"Radiother. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0360-3016(89)90917-6","article-title":"Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study","volume":"16","author":"Overgaard","year":"1989","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0360-3016(89)90343-X","article-title":"A phase I\/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: A RTOG randomized study (#79-04)","volume":"16","author":"Lee","year":"1989","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","article-title":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85","volume":"46","author":"Overgaard","year":"1998","journal-title":"Radiother. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0167-8140(02)00284-0","article-title":"Treatment of head and neck cancer with CHART and nimorazole: Phase II study","volume":"66","author":"Henk","year":"2003","journal-title":"Radiother. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/0284186X.2019.1658897","article-title":"A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma","volume":"58","author":"Andersen","year":"2019","journal-title":"Acta Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1158\/1078-0432.CCR-20-4128","article-title":"Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer","volume":"27","author":"Skwarski","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/codi.12281","article-title":"Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer","volume":"15","author":"Barsukov","year":"2013","journal-title":"Colorectal. Dis."},{"key":"ref_40","first-page":"268","article-title":"The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum","volume":"3","author":"Saunders","year":"1978","journal-title":"Br. J. Cancer Suppl."},{"key":"ref_41","first-page":"509","article-title":"Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors","volume":"6","author":"Overgaard","year":"1994","journal-title":"Oncol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2015.04.005","article-title":"IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nhimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma","volume":"116","author":"Ali","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2009.10.008","article-title":"HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer","volume":"94","author":"Lassen","year":"2010","journal-title":"Radiother. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1200\/JCO.2010.28.3085","article-title":"More lessons learned from the suffocation of hypoxia","volume":"28","author":"Ang","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13014-018-0984-3","article-title":"Hypoxia imaging with 18F-FAZA PET\/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts","volume":"13","author":"Melsens","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1269\/jrr.46.453","article-title":"Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo","volume":"46","author":"Sugie","year":"2005","journal-title":"J. Radiat. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2307\/3574491","article-title":"Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers","volume":"67","author":"Adams","year":"1976","journal-title":"Radiat. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dks504","article-title":"Antimalarial pharmacology and therapeutics of atovaquone","volume":"68","author":"Nixon","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1038\/ncomms5029","article-title":"Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action","volume":"5","author":"Birth","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1073\/pnas.89.23.11126","article-title":"Requirement for coenzyme Q in plasma membrane electron transport","volume":"89","author":"Sun","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/0006-2952(92)90213-3","article-title":"Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4\u2032-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)","volume":"43","author":"Fry","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1074\/jbc.272.7.3961","article-title":"Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite","volume":"272","author":"Srivastava","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12308","DOI":"10.1038\/ncomms12308","article-title":"The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia","volume":"7","author":"Ashton","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2015-07-660506","article-title":"Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent","volume":"128","author":"Xiang","year":"2016","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/bloodadvances.2019000499","article-title":"Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation","volume":"3","author":"Stevens","year":"2019","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-18-1286","article-title":"Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2\/\u03b2-Catenin Signaling","volume":"18","author":"Gupta","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"34084","DOI":"10.18632\/oncotarget.9122","article-title":"Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells","volume":"7","author":"Fiorillo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_58","first-page":"1697","article-title":"Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma","volume":"8","author":"Gao","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.bbrc.2018.04.042","article-title":"Targeting mitochondrial respiration as a therapeutic strategy for cervical cancer","volume":"499","author":"Tian","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative Phosphorylation as an Emerging Target in Cancer Therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e02242","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1158\/1078-0432.CCR-13-1787","article-title":"Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response","volume":"19","author":"Zannella","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2017.03.024","article-title":"Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy","volume":"98","author":"Mistry","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4694\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:40:27Z","timestamp":1760143227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":63,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194694"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194694","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]}}}